These top-line results ought to boost Brilinta’s sales, which have been disappointing to date; however, the magnitude of the boost will depend a lot on the actual risk reduction observed in this trial, which wasn't disclosed today. Moreover, generic Plavix remains an obstacle to commercial uptake.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.